Karin Lundin

Title: Karin Lundin: Innovator in Huntington's Disease Research

Introduction

Karin Lundin is a notable inventor based in Malmkoping, Sweden. She has made significant contributions to the field of genetic research, particularly in the context of Huntington's disease. Her innovative work focuses on therapeutic methods that aim to address this challenging condition.

Latest Patents

Karin Lundin holds a patent for a therapeutic method for Huntington's disease. The invention involves anti-gene oligonucleotides designed to hybridize with DNA in the HTT gene. These oligonucleotides are based on locked nucleic acids and phosphorodiamidate morpholino oligomers (PMO). They target sequences where the majority of repeats are CAG/CTG, effectively down-regulating the expression of the HTT gene. This results in reduced HTT mRNA and protein levels in affected individuals. The invention also includes a delivery system for these oligonucleotides, which can be utilized in the diagnosis, treatment, and prevention of Huntington's disease.

Career Highlights

Throughout her career, Karin has demonstrated a strong commitment to advancing medical research. Her innovative approach to Huntington's disease has positioned her as a key figure in the field. With a focus on genetic therapies, she continues to explore new avenues for treatment and prevention.

Collaborations

Karin Lundin has collaborated with several professionals in her field, including Rula Zain-Luqman and C I Edvard Smith. These partnerships have enhanced her research efforts and contributed to the development of her patented methods.

Conclusion

Karin Lundin's work in the realm of Huntington's disease represents a significant advancement in therapeutic methods. Her innovative approach and dedication to research continue to inspire progress in genetic therapies.